Physician profile
Melisa B Lyles
NPI 1861693525
$1,057.41
in general payments reported to CMS, 2019-2025
12 companies · $177 in 2025
The $177 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.34 · 2020: $43.79 · 2021: $24.47 · 2022: $207 · 2023: $213 · 2024: $307 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $696.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $207.90 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Sanofi-Aventis U.S. LLC | $154.65 | 2023-2025 | |
| Glaxosmithkline, LLC. | $134.53 | 2019-2024 | Bexsero |
| Corium, LLC | $122.53 | 2022-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $119.69 | 2022-2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $111.39 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $97.01 | 2022-2024 | Vaxneuvance, Gardasil 9, Proquad |
| Kaleo, INC. | $49.19 | 2019-2023 | Auvi-Q |
| Amneal Pharmaceuticals LLC | $16.13 | 2019 | |
| Collegium Pharmaceutical, INC. | $16.08 | 2025 | Jornay Pm |
| Sanofi Pasteur INC. | $14.45 | 2025 | |
| Alk-Abello, INC | $13.86 | 2023 | Odactra, Ragwitek, Grastek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melisa Lyles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.